Stock Financial Ratios

CRSP / CRISPR Therapeutics AG financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Market Cap ($M)214.63
Enterprise Value ($M)-53.22
Book Value ($M)232.85
Book Value / Share19.00
Price / Book0.94
NCAV ($M)322.96
NCAV / Share26.35
Price / NCAV7.02
Income Statement (mra) ($M)
Net Income-23.20
Balance Sheet (mrq) ($M)
Cash & Equivalents253.52
Cash / Share20.68
Quick Ratio14.56
Current Ratio14.56
Management Effectiveness (mra)
Return on Invested Capital (ROIC)-0.10
Return on Assets (ROA)-0.07
Return on Equity (ROE)-0.10
Identifiers and Descriptors
Central Index Key (CIK)1674416
Industry Groups
Share Statistics
Common Shares Outstanding (M)41.02
Scoring Models
Piotroski F Score2.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Kaplan-Zingales KZ-IndexN/A
Cash Conversion CycleN/A
Per Share Metrics
Inventory Raw Materials Per Share0.00
Long Term Debt Per Share0.00
Property Plant And Equipment Per Share1.60
Treasury Stock Per Share0.00
Accounts Payable Per Share0.00
Inventory Per Share0.00
Liabilities Per Share8.43
Liabilities And Stock Equity Per Share23.03
Intangibles Per Share0.00
Assets Current Per Share21.10
Inventory Work In Progress Per Share0.00
Liabilities Other Non Current Per Share0.01
Goodwill Per Share0.00
Property Plant And Equipment Gross Per Share1.85
Retained Earnings Per Share-10.25
Property Plant And Equipment Net Per Share1.60
Debt Per Share0.00
Deferred Income Tax Liabilities Per Share0.00
Assets Other Non Current Per Share0.05
Current Portion Of Long Term Debt Per Share0.00
Cash Per Share20.68
Equity Per Share14.60
Assets Other Current Per Share0.00
Accounts Receivable Per Share0.26
Inventory Finished Goods Per Share0.00
Preferred Stock Value Outstanding Per Share0.00
Assets Non Current Per Share0.00
Cash And Equivalents Per Share20.68
Assets Per Share23.03
Additional Paid In Capital Per Share24.74
Accumulated Depreciation And Depletion Per Share0.25
Liabilities Current Per Share0.99
Minority Interest Per Share0.00

Related News Stories

2018 Strategic Outlook: Will Fortune Favor The Bold In Biotech?

2018-01-16 seekingalpha
Significant scientific and technological breakthroughs, combined with unabated M&A appetite and tax reform, provide fertile ground for biotech gains in 2018. (302-2)

CRISPR Therapeutics: Buy The Secondary

2018-01-15 seekingalpha
Preclinical data provides rationale for ushering the program forward and their CAR-T efforts should not be overlooked. (25-1)

Your Daily Pharma Scoop: Lipocine's Gloomy Future, Puma Labeling Change, Concert's Mixed Day

2018-01-13 seekingalpha
Puma plans to modify labeling in its European marketing application for its breast cancer candidate neratinib. (254-4)

CRISPR And Axovant: What The Market Thinks

2018-01-12 seekingalpha
Let's go to the NASDAQ for some insight on a couple of recent biopharma stories. First off is Axovant (NASDAQ:AXON), a company that's interesting in a number of distressing ways. I last wrote about them here, after their Alzheimer's candidate came up short in the clinic, which was a development that surprised no one who had been paying attention. The same compound has now failed in a trial for Lewy body dementia, surprising no one who has been paying attention. (235-1)

4th-Quarter 2017 Portfolio Review And Price Increase For Integrated BioScI Investing

2018-01-11 seekingalpha
Since the Kite Pharma acquisition, other stellar performers continued to procure gargantuan profits, including Nektar, Amicus, Spectrum, and Alpine (following by the substantial winnings from new portfolio additions). (132-2)

CUSIP: H17182108